Physician profile
Mark B Blick
NPI 1811912041
$11,101.89
in general payments reported to CMS, 2019-2025
46 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $528 · 2021: $600 · 2022: $2,347 · 2023: $2,371 · 2024: $2,082 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,128 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,128.41 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,807.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,241.20 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,145.48 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $870.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $771.93 | 2019-2025 | Krystexxa, Repatha, Repatha |
| Lilly USA, LLC | $721.54 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $528.54 | 2022-2025 | |
| Esperion Therapeutics, INC. | $514.14 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $345.42 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $341.65 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $335.23 | 2022-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $257.86 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.07 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.71 | 2022-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $173.49 | 2021-2025 | Dexcom G6 Transmitter |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $167.95 | 2022-2025 | Veozah |
| Sumitomo Pharma America, INC. | $135.81 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $133.35 | 2021-2025 | |
| Amarin Pharma, INC. | $127.92 | 2019-2023 | |
| Boston Scientific Corporation | $125.00 | 2019-2020 | |
| Pfizer INC. | $101.58 | 2022-2025 | |
| Abbott Laboratories | $98.57 | 2021-2023 | Freestyle Libre 3 |
| Antares Pharma, INC. | $98.15 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $68.98 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $68.54 | 2024-2025 | Korlym |
| Scilex Pharmaceuticals INC. | $57.50 | 2019-2023 | Ztlido |
| Paratek Pharmaceuticals, INC. | $53.70 | 2025 | Xhance, Nuzyra |
| Verity Pharmaceuticals INC. | $42.99 | 2024-2025 | Tlando |
| Merck Sharp & Dohme LLC | $41.75 | 2022-2023 | Belsomra, Steglatro |
| Halozyme INC | $35.21 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $32.97 | 2022-2024 | Livalo |
| Almatica Pharma LLC | $30.83 | 2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $29.09 | 2019 | |
| Medtronic, INC. | $25.00 | 2021 | |
| Nestle Healthcare Nutrition INC. | $23.21 | 2022 | |
| Eisai INC. | $22.90 | 2022 | |
| Hologic Sales and Service, LLC | $22.69 | 2024 | Thinprep 2000 Processor, Aptima |
| Lundbeck LLC | $18.81 | 2023 | Rexulti |
| Philips North America LLC | $17.49 | 2023 | |
| Amneal Pharmaceuticals LLC | $17.13 | 2024 | Unithroid |
| Radius Health, INC. | $15.91 | 2020 | |
| Azurity Pharmaceuticals, INC. | $14.02 | 2025 | Azmiro |
| Allergan, INC. | $14.00 | 2019 | |
| Genentech USA, INC. | $14.00 | 2019 | |
| Ibsa Pharma INC. | $13.43 | 2022 | |
| Optinose US, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Blick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.